Australia - English - Department of Health (Therapeutic Goods Administration)

nova pharmaceuticals australasia pty ltd - caffeine, quantity: 100 mg - capsule, soft - excipient ingredients: sunset yellow fcf; purified water; macrogol 400; peg-40 hydrogenated castor oil; simethicone; partially dehydrated liquid sorbitol; glycerol; citric acid; isopropyl alcohol; titanium dioxide; gelatin; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - relieves mental fatigue, drowsiness and general inertia

United States - English - NLM (National Library of Medicine)

auromedics pharma llc - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine citrate 20 mg in 1 ml - caffeine citrate injection, usp is indicated for the treatment of apnea of prematurity. caffeine citrate injection is contraindicated in patients who have demonstrated hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine citrate 20 mg in 1 ml - caffeine citrate injection is indicated for the treatment of apnea of prematurity. caffeine citrate injection is contraindicated in patients who have demonstrated hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine citrate 20 mg in 1 ml - caffeine citrate is indicated for the treatment of apnea of prematurity. caffeine citrate is contraindicated in patients who have demonstrated hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine citrate 20 mg in 1 ml - caffeine citrate injection is indicated for the treatment of apnea of prematurity. caffeine citrate is contraindicated in patients who have demonstrated hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine citrate 20 mg in 1 ml - caffeine citrate oral solution is indicated for the short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age. caffeine citrate is contraindicated in patients who have demonstrated hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

american regent, inc. - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine citrate 20 mg in 1 ml - caffeine citrate injection is indicated for the treatment of apnea of prematurity. caffeine citrate injection is contraindicated in patients who have demonstrated hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

american regent, inc. - caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - caffeine 125 mg in 1 ml - caffeine and sodium benzoate injection has been used in conjunction with supportive measure to treat respiratory depression associated with overdosage with cns depressant drugs (e.g., narcotic analgesics, alcohol). however, because of questionable benefit and transient action, most authorities believe caffeine and other analeptics should not be used in these conditions and recommend other supportive therapy. none known.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - caffeine, quantity: 12.5 mg - oral liquid, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injections - cafnea oral solution is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - caffeine, quantity: 20 mg - injection, intravenous infusion - excipient ingredients: sodium citrate dihydrate; water for injections; citric acid monohydrate - cafnea injection is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.